Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
Oct. 3, 2019: The sexual divide in HIV-related heart disease; weight gain among women on integrase inhibitors; HIV's association with non-specific health conditions; hopeful trends in self-reported neurocognitive impairment.
Aug. 22, 2019: Links between thiamine deficiency and cognitive issues; HIV in cerebrospinal fluid and neurocognitive impairment; frailty, depression, and symptomatic cognitive issues; alcohol consumption and HIV disease progression.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.
More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.